Healthcare

Actinogen Medical Limited (ASX:ACW)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.1550.005 (3.333%)

(as on 2022-01-17 12:05:14 AEDT)

Market Cap : AUD 275.101 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.15 0.155 0.155 0.150L 0.155 H 0.019L 0.198 H
Last Trade 0.155
Change% 3.3333
52 W H/L 0.198/0.019
EBITDA -3.506 M
NPAT After Abnormal Items -3.915 M
Equity 17.458 M
ROE% -22.43%
Total Liabilities 920,321
Total Revenue 1.984 M
Cash and Cash Equivalents 13.422 M

Stock Information

Share price 0.155
Market Cap 275.101 M
Price/Gross Cash Flow -91.58
Dividend Yield Excluding Special 0.00%
Ending Shares 1.661 B
52-Week Range 0.198-0.019
P/E ratio 0.000
Sector P/E --
EPS -0.28
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.00
Net Gearing -75.52%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.01
Sales Per Share 0.00
Book Value Per Share 0.01

Announcements

Heading Date/Time
Results of Annual General Meeting  10/11/2021 1:02PM
AGM Presentations  10/11/2021 9:33AM
ACW announces open IND for Phase 2 Fragile X trial & LOI  09/11/2021 9:58AM
Quarterly Activity Report & Appendix 4C  20/10/2021 10:20AM
R&D Tax Incentive Rebate received of A$1.435 million  13/10/2021 9:12AM
Annual Report to Shareholders  08/10/2021 11:50AM
Letter to Shareholders & Notice of Annual General Meeting  08/10/2021 11:44AM
Date of AGM and Closing Date for Director Nominations  22/09/2021 5:58PM
Application for quotation of securities - ACW  16/09/2021 4:15PM
Appendix 4G  30/08/2021 4:37PM
Actinogen Medical FY21 Results- Progressing the Pipeline  30/08/2021 4:36PM
Appendix 4E & Annual Report  30/08/2021 4:34PM
Actinogen completes global patent family grant  23/08/2021 9:19AM
Actinogen to present at ShareCafe Small Cap Webinar  04/08/2021 9:06AM
Quarterly Activity Report & Appendix 4C  22/07/2021 9:19AM
First Patient Enrolled in XanaMIA trial  15/07/2021 9:34AM
Actinogen receives positive Pre-IND FDA advice for FXS  23/06/2021 9:40AM
Clinical progress for XanaMIA trial  21/06/2021 9:29AM
Actinogen Ethics Committee approval for XanaMIA study  02/06/2021 9:17AM
Change of Share Register Notification  28/05/2021 8:37AM
Response to ASX Price Query  24/05/2021 4:43PM
Lapse of Unlisted Options  10/05/2021 8:39AM
Strategic Update Teleconference Transcript  30/04/2021 11:34AM
Strategic Update & Teleconference Call Notification  21/04/2021 9:11AM
Quarterly Activity Report & Appendix 4C  21/04/2021 8:23AM
Appendix 3Y - Dr George Morstyn  29/03/2021 11:27AM
Initial Director's Interest Notice  24/03/2021 9:39AM
Actinogen CEO assumes Managing Director position  24/03/2021 9:35AM
Appendix 2A  15/03/2021 5:02PM

Similar Companies

Related Articles

About Company

Actinogen Medical is an Australian based biotechnology company. The company is engaged in the treatment of age-related neurodegenerative diseases and Alzheimer. The company focuses on treating cognitive decline through the development of lead compound Xanamem that blocks the production of cortisol in the brain.

Corporate Information

company address Suite 901, Level 9, 109Pitt Street, SYDNEY, NSW, AUSTRALIA, 2000

company phone+61 2 8964 7401

company websitehttp://www.actinogen.com.au

Dividends

Year-end Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-10-07 2022
Report (Annual) 2022-08-29 2022
Report (Prelim) 2022-08-29 2022
Report (Interim) 2022-02-23 2022
Issued Shares 2022-01-17 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue -- -- -- -- --
Other Revenue 1.984 M 3.516 M 4.863 M 3.304 M 1.378 M
Total Revenue 1.984 M 3.516 M 4.863 M 3.304 M 1.378 M
Interest Income 27,090 94,057 204,546 38,715 37,535
Interest Expenses -22,318 -28,882 -7,987 -11,457 -8,532
Expenses -5.517 M -8.499 M -14.117 M -9.206 M -4.237 M
EBITDA -3.533 M -4.983 M -9.254 M -5.902 M -2.859 M
Depreciation and Amortization -386,695 -412,933 -353,500 -356,040 -360,618
Depreciation -73,948 -99,331 0 -2,540 -7,117
Amortisation -312,747 -313,602 -353,500 -353,500 -353,501
EBIT -3.92 M -5.396 M -9.607 M -6.258 M -3.219 M
Pre Tax Profit -3.915 M -5.331 M -9.411 M -6.231 M -3.19 M
Tax Expense 0 0 0 0 0
Net Profit After Tax -3.915 M -5.331 M -9.411 M -6.231 M -3.19 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 -476,900 0 0
Reported Net Profit After Abnormal Items -3.915 M -5.331 M -9.888 M -6.231 M -3.19 M
Ending Shares 1.661 B 1.139 B 1.142 B 959.507 M 632.851 M
Weighted Average Shares 1.405 B 1.141 B 1.125 B 719.484 M 621.439 M
EPS After Abnormal Items (cents) -0.28 -0.47 -0.88 -0.87 -0.51
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 15.056 M 8.164 M 12.527 M 13.536 M 5.364 M
Total Non Current Assets 3.322 M 3.772 M 3.695 M 4.49 M 4.846 M
Total Assets 18.378 M 11.936 M 16.222 M 18.026 M 10.21 M
Total Current Liabilities 755,050 743,816 557,395 768,253 844,259
Total Non Current Liabilities 165,271 303,852 0 0 0
Total Liabilities 920,321 1.048 M 557,395 768,253 844,259
Net Assets 17.458 M 10.889 M 15.665 M 17.258 M 9.366 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash -1.724 M -2.856 M -10.498 M -7.911 M -1.109 M
Net Invested Cash -6,188 -22,760 71,771 2.06 M 1.981 M
Net Financing Cash Flows 10.111 M 282,258 8.166 M 13.96 M 270,000
Beginning Cash 5.04 M 7.637 M 9.897 M 1.895 M 751,978
End Cash Position 13.422 M 5.04 M 7.637 M 10.004 M 1.895 M
Exchange Rate Adjustments 0 0 0 0 0
Other Cash Adjustments 0 0 0 0 0
Ending Cash 13.422 M 5.04 M 7.637 M 10.004 M 1.895 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK